Results 1 to 10 of about 37,893 (278)

Advances in the design and development of oncolytic measles viruses [PDF]

, 2015
A successful oncolytic virus is one that selectively propagates and destroys cancerous tissue without causing excessive damage to the normal surrounding tissue. Oncolytic measles virus (MV) is one such virus that exhibits this characteristic and thus has
Adam Studebaker, Corey Raffel, Brian Hutzen   +2 more
openalex   +4 more sources

BRD9 inhibition overcomes oncolytic virus therapy resistance in glioblastoma [PDF]

Cell Reports Medicine
Summary: Long-term survival of glioblastoma multiforme (GBM) remains challenging, spurring the development of novel therapies such as oncolytic virus therapy.
Chen Guo, Zhilin Long, Peng Lin, Yinan Shen, Yiye Zhong, Jingjing Qian, Jichuan Yu, Weixi Zhao, Fuyi Liu, Yiling Ma, Jian Zheng, Jiayao Yang, Shuai Zhao, Xiaojuan Ran, Zhen Xia, Congying Wu, Yujia Cai, Chen Wang, Qi Xie   +18 more
doaj   +2 more sources

Sorting out Pandora’s box: discerning the dynamic roles of liver microenvironment in oncolytic virus therapy for hepatocellular carcinoma [PDF]

Frontiers in Oncology, 2014
Oncolytic viral therapies have recently found their way into clinical application for hepatocellular carcinoma (HCC), a disease with limited treatment options and poor prognosis. Adding to the many intrinsic challenges of in vivo oncolytic viral therapy,
Oliver eEbert, Jennifer eAltomonte
doaj   +4 more sources

Chinese expert consensus on clinical application of recombinant oncolytic adenovirus in the treatment of malignant tumors [PDF]

Zhongguo aizheng zazhi, 2023
Treatment using oncolytic virus as a new tumor immunologic agent has made continuous breakthroughs in basic and clinical research of tumor in recent years, and it is expected to play an important role in cancer immunotherapy in the future.
Expert Committee on Immunotherapy of Chinese Society of Clinical Oncology , Professional Committee on Cancer Biotherapy of Shanghai Anticancer Association
doaj   +1 more source

Cell cycle progression or translation control is not essential for vesicular stomatitis virus oncolysis of hepatocellular carcinoma. [PDF]

, 2010
The intrinsic oncolytic specificity of vesicular stomatitis virus (VSV) is currently being exploited to develop alternative therapeutic strategies for hepatocellular carcinoma (HCC). Identifying key regulators in diverse transduction pathways that define
A Bianchini, A Villanueva, Alexandra Junger, Antonia Rizzani, DA Altomare, EF Dunn, Enrico N. De Toni, Günter Schneider, HG Wendel, I Fabregat, I Nicoletti, IBCJ Rosenwald, JE Dancey, Jennifer Altomonte, JH Connor, JS Orlando, K Shinozaki, K Shinozaki, L Mishra, LM Schang, M Ahmed, M Hidalgo, M Ikeda, M Sun, Maciej Lesniak, N Kato, N Kato, N Kemeny, N Sonenberg, NA Hamid, Nobuyuki Kato, O Ebert, O Ebert, O Larsson, Oliver Ebert, P Chakraborty, P Newell, PC Chiang, PL Hallenbeck, RB Kjellerup, RL Silva, RM Memmott, Roland M. Schmid, S Balachandran, S Joshi, S Marozin, S Oliere, S Sei, S Sell, Sabrina Marozin, SM Steinberg, SR Kimball, T Cascone, T Nakamura, T Ueda, TL Nguyen, TP Cripe, WE Thasler, Wolfgang E. Thasler, XQ Lun, Y Ma   +60 more
core   +11 more sources

Oncolytic H-1 parvovirus binds to sialic acid on laminins for cell attachment and entry

Nature Communications, 2021
Rat H-1 parvovirus (H-1PV) is in clinical development for oncolytic therapy. Here, Kulkarni et al. identify LAMC1 as a modulator of H-1PV cell attachment and entry and find that LAMC1 levels and H-1PV oncolytic activity correlate in 59 tested cancer cell
Amit Kulkarni, Tiago Ferreira, Clemens Bretscher, Annabel Grewenig, Nazim El-Andaloussi, Serena Bonifati, Tiina Marttila, Valérie Palissot, Jubayer A. Hossain, Francisco Azuaje, Hrvoje Miletic, Lars A. R. Ystaas, Anna Golebiewska, Simone P. Niclou, Ralf Roeth, Beate Niesler, Amélie Weiss, Laurent Brino, Antonio Marchini   +18 more
doaj   +1 more source

Oncolytic H-1 Parvovirus Hijacks Galectin-1 to Enter Cancer Cells

Viruses, 2022
Clinical studies in glioblastoma and pancreatic carcinoma patients strongly support the further development of H-1 protoparvovirus (H-1PV)-based anticancer therapies. The identification of cellular factors involved in the H-1PV life cycle may provide the
Tiago Ferreira, Amit Kulkarni, Clemens Bretscher, Petr V. Nazarov, Jubayer A. Hossain, Lars A. R. Ystaas, Hrvoje Miletic, Ralph Röth, Beate Niesler, Antonio Marchini   +9 more
doaj   +1 more source

The XVIII International Parvovirus Workshop Rimini, Italy, 14–17 June 2022

Viruses, 2023
The XVIII International Parvovirus Workshop took place in Rimini, Italy, from 14 to 17 June 2022 as an on-site event, continuing the series of meetings started in 1985 and continuously held every two years.
Giorgio Gallinella, Antonio Marchini
doaj   +1 more source

Single-cell RNA sequencing reveals a strong connection between Gadd45g upregulation and oncolytic HSV infection in tumor tissue

Molecular Therapy: Oncolytics, 2021
The oncolytic effect of virotherapy derives from the intrinsic capability of the applied virus in selectively infecting and killing tumor cells. Although oncolytic viruses of various constructions have been shown to efficiently infect and kill tumor ...
Divya Ravirala, Guangsheng Pei, Zhongming Zhao, Xiaoliu Zhang   +3 more
doaj   +1 more source

Oncolytic H-1 Parvovirus Enters Cancer Cells through Clathrin-Mediated Endocytosis

Viruses, 2020
H-1 protoparvovirus (H-1PV) is a self-propagating virus that is non-pathogenic in humans and has oncolytic and oncosuppressive activities. H-1PV is the first member of the Parvoviridae family to undergo clinical testing as an anticancer agent.
Tiago Ferreira, Amit Kulkarni, Clemens Bretscher, Karsten Richter, Marcelo Ehrlich, Antonio Marchini   +5 more
doaj   +1 more source